For CPT 2006, code 90649 , Human papilloma virus (HPV) vaccine, types 6, 11, 16, 18 (quadrivalent), 3 dose schedule, for intramuscular use, was designated with an Food and Drug Administration (FDA) approval pending symbol. Upon review of the 2007 CPT codebook, I realize that the designation is no longer applied to code 90649 . The removal of the FDA approval pending symbol leads one to believe that code 90649 has now received FDA approval. Is this correct? If so, is it appropriate to report code 90649 for either males or females, or is it only applicable to female patients? ...

Subscribe or sign in to view the full article.

Sign In Subscribe Today

Note:  The following article synopsis was NOT provided by the AMA. It was created by Find-A-Code/innoviHealth.

Article Overview

This article addresses a CPT coding question about a vaccine code’s appearance in one year’s codebook versus a later year, and what that change may indicate about FDA approval status. It is intended for coding professionals who need to interpret CPT editorial symbols, understand the general impact of FDA approval updates, and evaluate broad reporting considerations tied to the code’s scope. The discussion stays focused on the code’s publication history, FDA context, and patient-related reporting applicability at a high level.

Why This Topic Matters

Coding staff and compliance reviewers often need to know whether a CPT code’s editorial status has changed across annual codebooks and what that means for documentation and reporting. Clarifying the relationship between CPT symbol changes and FDA approval helps reduce confusion when reviewing vaccine-related claims and code references.

Codes Discussed

• CPT: 90649

Subscribe or sign in to view the full article.

Sign In Subscribe Today